G. J. Lesser

Phase 2 study of dose-intense temozolomide in recurrent glioblastoma

Andrew D. Norden, G. J. Lesser, Jan Drappatz et al. · Neuro-Oncology · 2013 · 90 citations · Full text

A Phase I Dose Escalation Study of Hypofractionated IMRT Field-in-Field Boost for Newly Diagnosed Glioblastoma Multiforme

Arta M. Monjazeb, Deandra Ayala, Courtney A. Jensen et al. · International Journal of Radiation Oncology*Biology*Physics · 2011 · 42 citations · Full text

Neuro-oncology, Radiation Therapy, Glioblastoma Multiforme +9

Phase II study of dose-intense temozolomide in recurrent glioblastoma.

Sue Hammond, Andrew D. Norden, G. J. Lesser et al. · Journal of Clinical Oncology · 2011 · 12 citations

Dose-intense Temozolomide, Pathology, Pharmacotherapy +17

Phase II study of monthly pasireotide LAR (SOM230C) for recurrent or progressive meningioma.

Andrew D. Norden, Stephen T. Hammond, Jan Drappatz et al. · Journal of Clinical Oncology · 2011 · 12 citations

Neuro-oncology, Endocrine Oncology, Monthly Pasireotide Lar +13

Rituximab monotherapy for relapsed or refractory primary central nervous system lymphoma

Tracy T. Batchelor, G. J. Lesser, Stuart A. Grossman · Journal of Clinical Oncology · 2008 · 11 citations